Muhammad Salman Sabri, Zinya Talukder, Angad Bedi, Sung-Hae Cho
{"title":"When delivery matters: Diffuse coronary vasospasm with continuous, but not bolus, 5-FU infusion.","authors":"Muhammad Salman Sabri, Zinya Talukder, Angad Bedi, Sung-Hae Cho","doi":"10.21542/gcsp.2025.61","DOIUrl":null,"url":null,"abstract":"<p><p>5-Fluorouracil (5-FU) is a fluorinated pyrimidine chemotherapy analogue used to treat various gastrointestinal solid malignancy. It is known to be associated with cardiotoxicity. Here, we present a case of 58-year-old male with mucinous adenocarcinoma of the sigmoid colon who experienced global coronary vasospasm in setting of continuous 5-FU infusion refractory to prophylactic antianginal treatment. However, he was asymptotic when given bolus of 5-FU. Our case highlights the difference in toxicity between continuous and bolus 5-FU therapy and emphasizes the need for further research in the pathophysiology and treatment of cardiotoxicity related to 5-FU therapy.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2025 6","pages":"e202561"},"PeriodicalIF":0.0000,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070258/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Cardiology Science & Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21542/gcsp.2025.61","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
5-Fluorouracil (5-FU) is a fluorinated pyrimidine chemotherapy analogue used to treat various gastrointestinal solid malignancy. It is known to be associated with cardiotoxicity. Here, we present a case of 58-year-old male with mucinous adenocarcinoma of the sigmoid colon who experienced global coronary vasospasm in setting of continuous 5-FU infusion refractory to prophylactic antianginal treatment. However, he was asymptotic when given bolus of 5-FU. Our case highlights the difference in toxicity between continuous and bolus 5-FU therapy and emphasizes the need for further research in the pathophysiology and treatment of cardiotoxicity related to 5-FU therapy.